A French medical know-how startup centered on “reworking prenatal drugs” just lately gained $14 million in Collection A funding.
The Paris-based firm, named Sonio, has now raised $20 million because it was based in 2020. Its Collection A financing spherical was led by Cross Border Affect Ventures and Elaia.
Sonio’s AI platform automates ultrasound reporting. The know-how is supposed to allow healthcare suppliers to conduct ultrasound exams with better accuracy, velocity and effectivity, CEO Cécile Brosset informed MedCity Information.
“We’re centered on streamlining the end-to-end workflow for practitioners — from sharing the ultrasound photos with the sufferers to reporting, and from high quality assurance to anomaly detection. We need to cowl each small process and optimize the medical time being utilized. Our intention is to cut back healthcare consultants’ time to do low-value-added duties, to allow them to concentrate on different essential features,” she declared.
The corporate receives photos as they’re acquired by the sonographer, whatever the ultrasound machine’s mannequin or model, Brosset defined. Sonio’s AI platform then processes these photos within the cloud and gives practitioners with a real-time evaluation. The startup claims that its know-how can determine greater than 300 potential prenatal syndromes and anomalies with an accuracy fee of not less than 95%.
Sonio’s platform additionally features a medical resolution help software designed to prioritize potential uncommon diagnoses.
“It’s skilled on professional literature explaining which indicators are most likely related to totally different pathologies. Any such AI doesn’t be taught from photos, however from proprietary text-based medical databases. It mainly mimics medical reasoning via a really advanced statistical resolution tree,” Brosset mentioned.
The corporate sells its software program to hospitals, girls’s well being teams and personal doctor practices. These suppliers should purchase both a month-to-month or yearly subscription.
Brosset recognized GE HealthCare, Ultrasound.ai, Diagnoly and AS Software program as a few of Sonio’s largest rivals. When requested how her startup units itself aside from these corporations, she mentioned that Sonio’s objective “is not only to develop superior tech, however to avoid wasting lives with the assistance of the tech” — but it surely’s most likely protected to imagine that Sonio’s rivals are eager on saving lives as effectively.
With its new fundraise, Sonio plans to broaden its crew and provoke its industrial growth within the U.S.
The corporate’s know-how has been cleared to be used in Europe, but it surely hasn’t been cleared by the FDA but. Brosset declined to reply MedCity’s query about whether or not there’s a reimbursement path for Sonio’s know-how.
Picture: Blue Planet Studio, Getty Photographs
